Krenning E P, Kwekkeboom D J, Oei H Y, Reubi J C, van Hagen P M, Kooij P P, Reijs A E, Lamberts S W
Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands.
Schweiz Med Wochenschr. 1992 Apr 25;122(17):634-7.
Somatostatin receptors are present on various tumors of neuroendocrine origin. We recently developed a technique for the in vivo visualization of somatostatin receptor positive tumors, which offers a powerful alternative to tumor imaging with labeled monoclonal antibodies. Instead of injecting radiolabeled antibodies against the somatostatin receptor, we labeled a somatostatin analogue ([Tyr3]-octreotide) which is known to bind specifically to the somatostatin receptor, and injected this labeled hormone analogue in order to visualize somatostatin receptor positive tumors. We previously reported the successful visualization of the primary tumors or metastases of various endocrine gastrointestinal tumors after injection of the iodinated somatostatin analogue [123I-Tyr3]-octreotide. The primary tumors or metastases of 12 out of 13 carcinoids, 3 out of 3 gastrinomas, 2 out of 4 insulinomas, and 1 out of 1 somatostatinoma were visualized. Using 111In-coupled octreotide, we were able to visualize 19 out of 19 carcinoids, 7 out of 7 gastrinomas, 4 out of 7 insulinomas, 1 out of 1 glucagonoma, and 3 out of 3 non-functioning endocrine pancreatic tumors, but none of 18 exocrine pancreatic tumors. In a large proportion of patients with endocrine gastrointestinal tumors, previously unrecognized metastases were demonstrated. Also, the absence or presence of in vivo visualization of these tumors after the injection of radiolabeled octreotide seems to predict the ability of octreotide therapy to control symptoms caused by hormonal secretion from these tumors.
111In-octreotide scintigraphy is a simple and sensitive technique for localizing of the primary tumor and its metastases in the majority of patients with carcinoids or endocrine pancreatic tumors.(ABSTRACT TRUNCATED AT 250 WORDS)
生长抑素受体存在于各种神经内分泌起源的肿瘤上。我们最近开发了一种用于体内可视化生长抑素受体阳性肿瘤的技术，这为用标记单克隆抗体进行肿瘤成像提供了一种强有力的替代方法。我们没有注射针对生长抑素受体的放射性标记抗体，而是标记了一种已知能特异性结合生长抑素受体的生长抑素类似物（[Tyr3]-奥曲肽），并注射这种标记的激素类似物以可视化生长抑素受体阳性肿瘤。我们之前报道了注射碘化生长抑素类似物[123I-Tyr3]-奥曲肽后，成功可视化了各种内分泌性胃肠道肿瘤的原发肿瘤或转移灶。13例类癌中的12例、3例胃泌素瘤中的3例、4例胰岛素瘤中的2例以及1例生长抑素瘤中的1例的原发肿瘤或转移灶被可视化。使用111In标记的奥曲肽，我们能够可视化19例类癌中的19例、7例胃泌素瘤中的7例、7例胰岛素瘤中的4例、1例胰高血糖素瘤中的1例以及3例无功能内分泌胰腺肿瘤中的3例，但18例胰腺外分泌肿瘤均未被可视化。在很大一部分内分泌性胃肠道肿瘤患者中，发现了之前未被识别的转移灶。此外，注射放射性标记奥曲肽后这些肿瘤在体内可视化的有无似乎可预测奥曲肽治疗控制这些肿瘤激素分泌所致症状的能力。
111In-奥曲肽闪烁扫描术是一种简单且敏感的技术，可用于定位大多数类癌或内分泌胰腺肿瘤患者的原发肿瘤及其转移灶。（摘要截短至250字）
